pathologic and compensatory functions in the heart, although a nonoverexpression approach is needed to better examine its gain-of-function effects and to determine if p38 really could be a relevant target for treating heart disease.
The duration, extent, and subcellular compartment for p38, JNK, and ERK1/2 phosphorylation are critical determinants of the physiological response to any given mitogenic or stress stimulation. The terminal MAPKs (ERK1/2, JNK, and p38) are either activated or inactivated through the phosphorylation status of the threonine and adjacent tyrosine residue within the activation loop of these kinases. [1] [2] [3] A specialized family of phosphatases has evolved that can dephosphorylate both serine/threonine and tyrosine residues within the activation loop, known as the dual-specificity protein phosphatases (DUSPs). There are 10 Dusp genes in the mouse genome that are specialized for the MAPKs and, hence, have been referred to as MAPK phosphatases (MKPs). 7 A unique feature of most MKPs/DUSPs is their regulation at the level of transcription after stress or mitogen stimulation, providing a negative feedback loop to dampen the extent and duration of MAPK signaling with a typical lag of 15 to 45 minutes. 7 Once expressed, DUSPs are constitutively active and capable of direct binding to the activation loop in MAPKs, resulting in dephosphorylation and their inactivation. Each of the 10 MKP/DUSP family members differs with respect to subcellular localization, tissue expression pattern, and exact specificity for ERK1/2 vs JNK1/2 vs p38.
7 DUSP1 (MKP-1) and DUSP4 (MKP-2) are each induced by stress stimulation in the heart or cultured myocytes with agonist treatment, where they then reside mostly within the nucleus (although some cytoplasmic localization is observed) and have the highest degree of action against p38 MAPK, followed by JNK and then ERK1/2. [7] [8] [9] [10] [11] [12] Although the function of the Dusp6 gene has been investigated in the heart, where it serves as an exclusive regulator of ERK1/2 signaling, with effects on hypertrophic growth and myocyte proliferation, 13, 14 the function of the p38 inactivating DUSPs has not been evaluated, nor have their roles in heart disease been characterized.
Methods
Dusp1-null mice were described previously. 15 The Dusp4 gene was targeted in embryonic stem cell using homologous recombination, after which gene-deleted mice were created using standard techniques. Mouse embryonic fibroblasts (MEFs) were generated from Dusp1/4 double-null embryos harvested at embryonic day 12.5 and cultured in 10% fetal bovine serum containing Dulbecco modified Eagle's medium. Echocardiography was performed with a Hewlett Packard SONOS 5500 with a 15-mHz probe and images were collected in M-mode. Cardiac pressure overload was induced by transverse aortic constriction (TAC) in young adult mice as described previously. 16 Myocytes were isolated from adult hearts and cultured for either Western blot analysis of MAPK phosphorylation or assessment of cellular shortening and Ca 2+ handling as described previously. 17 Results are shown as mean ± SEM, and significance between groups was evaluated by ANOVA or t test when appropriate. Detailed Materials are available in the Online Data Supplement.
Results
Generation of Dusp1/4 Double-Null Mice DUSP1, DUSP4, and DUSP10 are the major regulators of p38 MAPK dephosphorylation to allow inactivation and recycling of this kinase. Both DUSP1 and DUSP4 are induced by hypertrophic agonists in cultured cardiomyocytes or during heart failure, in which they contribute to MAPK inactivation. 10, 11, 18 Consistent with these previous observations, we observed an increase in DUSP1 and DUSP4 mRNA in the mouse heart after 7 days of hypertrophic pressure overload stimulation; however, by 8 weeks of stimulation when the heart is transitioning into failure, only DUSP4 remained high ( Figure 1A ). DUSP10, although expressed in the heart, was constitutively present and not subject to induction with hypertrophy ( Figure 1A ). To begin to address the physiologic relevance of DUSP function in the heart in regulating p38 MAPK during disease, we inactivated the Dusp4 gene by targeting this locus in embryonic stem cells for the generation of gene-deleted mice ( Figure 1B ). Reverse-transcriptase polymerase chain reaction confirmed the deletion of the gene product in the heart ( Figure 1C ). Given redundancy in function of Dusp4 with Dusp1, we crossed these 2 gene-deleted mice together, and for control purposes we also analyzed DUSP1 mRNA from these hearts, which confirmed gene deletion as previously shown ( Figure 1C ).
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Loss of Dusp1/4 Only Alters p38 MAPK Activity
Part of the rationale for generating Dusp1/4 double-null mice was based on our inability to consistently measure a difference in p38, JNK, or ERK1/2 phosphorylation in single Dusp1 or Dusp4 gene-targeted mouse hearts or MEFs in culture (data not shown). Again, this is likely attributable to redundancy and compensation among the Dusp gene family members, of which Dusp1 and Dusp4 appear to function most similarly with respect to specificity for p38.
7 Dusp1/4 double-null mice were viable and overtly normal, and fibroblasts from these mice proliferated normally (data not shown). Interestingly, Dusp1/4 −/− MEFs cultured in serumcontaining medium showed a remarkable and specific defect in p38 MAPK dephosphorylation at baseline, whereas none of the other MAPK family members were affected ( Figure  2A) . Specifically, phospho-p38 was dramatically increased at all times in Dusp1/4 −/− MEFs, with a corresponding downregulation of its upstream activator MKK6 ( Figure 2A) . As previously reported, activated p38 MAPK negatively regulates MKK6 mRNA stability, and thus decreases MKK6 expression in various cell types. 19 Downstream of p38, there was a constitutive increase in phosphorylation of MAPKactivated protein kinase 2 (MK2) at T222 and T334 in the absence of Dusp1/4, which are direct p38 MAPK target sites not affected by JNK or ERK1/2 ( Figure 2A 
Aniso: Figure  2B ). We next investigated MAPK responsiveness in the heart at baseline or with acute TAC stimulation for 15 minutes in the presence or absence of the p38 inhibitor SB731445 administered to the mice starting 2 days before surgery ( Figure 2C ). The data show greater p38 and MK2 activation at baseline in the hearts of Dusp1/4 −/− mice, with even greater activation after TAC stimulation compared with Wt controls ( Figure 2C , arrowheads). Hearts from Dusp1/4 −/− mice showed no changes in ERK1/2 or JNK1/2 phosphorylation at baseline or with TAC stimulation ( Figure 2C ). We also analyzed hearts from mice subjected to sham or TAC procedures for p38 and MK activation in either the cytoplasm or the nucleus (Online Figure I ). The data again show greater p38 and MK2 phosphorylation in hearts from Dusp1/4 −/− mice, both at baseline and with TAC stimulation, as well as greater MK2 nuclear content in the absence of Dusp1/4, again suggesting greater activation (Online Figure I) . We also injected 2-weekold Wt and Dusp1/4 −/− mice with anisomycin to induce a systemic stress response and, at select times thereafter, mice were euthanized and the hearts were removed for analysis of p38 MAPK phosphorylation ( Figure 2D ). Similar to the results observed in MEFs, anisomycin induced a transient increase in p38 MAPK phosphorylation in the hearts of Wt mice at 5 to 60 minutes, which was inactivated by 180 minutes. In contrast, hearts from Dusp1/4 −/− mice showed no inactivation up to 180 minutes and, in fact, activation attained a higher level as time progressed ( Figure 2D ). We also repeated this same type of analysis in Wt vs Dusp1/4 −/− mice subjected to pressure overload by TAC for varying lengths of time to gauge the temporal aspects of regulation within the heart more thoroughly ( Figure 2E ). Hearts from Wt mice showed variable and intermittent activation of p38 at different time periods of pressure overload, as shown previously. 20 In contrast, hearts from Dusp1/4 −/− mice subjected to TAC showed uniform and maximal p38 phosphorylation at every time point analyzed, with no periods of inactivation ( Figure 2E ). Taken together, these results suggest that loss of Dusp1/4 from the heart or cultured MEFs removes a break on p38 MAPK signaling, rendering this pathway unrestrained and with greater net activity.
Dusp1/4 −/− Mice Show Cardiomyopathy
Whereas Dusp1/4 −/− mice were overtly normal at birth and young adulthood, we did observe a significant decrease in survival with aging, such that by 8 months, 30% of the double-null mice had died compared with no lethality in Wt or single Dusp1-null or Dusp4-null mice ( Figure 3A) . We suspected that some of these mice may have died of heart failure, because careful analysis by echocardiography showed progressive dilation of the ventricular chambers in the doubleknockout (DKO) mice, reductions in fractional shortening, and secondary increases in heart weight normalized to body weight ( Figure 3B-3D) , although no increase in TUNEL was observed suggesting the failure was not associated with apoptosis (Online Figure II) . As a whole, Dusp1 and Dusp4 single-null mice showed no cardiac abnormalities up to 8 months of age, except for a small, albeit significant, reduction in fractional shortening in Dusp4 −/− mice at 8 months of age ( Figure 3B-D) . The large increase in heart weight observed in Dusp1/4 −/− mice at 8 months of age was characterized mostly by myocyte thinning, as measured from isolated adult myocytes from these hearts ( Figure 3E ), as well as frank dilation of the left ventricle at the whole-organ level ( Figure 3F ). Dusp1/4 DKO mice also were highly susceptible to lethality after TAC stimulation, showing their propensity toward rapid failure ( Figure 3G) , and the few DKO mice that survived this procedure to 14 days showed much greater cardiac hypertrophy than Wt controls (Online Figure III) . These phenotypic characteristics likely were attributable to unrestrained p38 MAPK activity, at least partially consistent with the cardiac phenotype described previously for transgenic mice overexpressing activated MKK3/MKK6. 4 Isolation and culturing (serum-free) of adult myocytes from hearts of wildtype vs Dusp1/4 −/− mice showed again that only p38 MAPK was hyperphosphorylated in double-null cells, with activation of the p38-specific downstream kinase MK2 ( Figure 3H ). No changes were observed in JNK or ERK1/2 phosphorylation, again suggesting that DUSP1/DUSP4 are the primary regulators of p38 MAPK dephosphorylation in the heart, and their absence permits unrestrained activity that is associated with cardiomyopathy.
Inhibition of p38 Protects Dusp1/4
−/− Mice From Cardiomyopathy DUSP1 and DUSP4 also can dephosphorylate JNK, albeit less efficiently than p38 MAPK. Moreover, there are other DUSPs with greater specificity for JNK over p38 that likely would compensate when Dusp1/Dusp4 are deleted. Our analysis of Dusp1/4 −/− MEFs and hearts failed to show any effect on JNK phosphorylation status, suggesting that the phenotype observed in the DKO mice was attributable solely to unrestrained p38 activity. However, to better establish specificity for p38 MAPK, we treated Dusp1/4 −/− mice with a selective and orally active p38 inhibitor, SB731445, which was formulated in mouse chow at a dosage of 50 mg/kg per day. Mice achieved a blood and heart tissue level of ≈350 ng/mL (or per gram for heart). In Wt control mice administered SB731445, we observed an increase in MKK6 phosphorylation in both heart and skeletal muscle, as well as an increase in total MKK6 protein, suggesting that p38 was inhibited because it normally reduces MKK6 expression through feedback, as discussed previously ( Figure 4A ). SB731445 binds to the ATP pocket in p38 and reduces its ability to phosphorylate substrates, but it does not prevent p38 itself from being phosphorylated and, hence, in skeletal muscle p38 was hyperphosphorylated because of greater MKK6 activity ( Figure 4A ). MK2 was hypophosphorylated (faster migration on a gel) in skeletal muscle and, to a lesser extent, in cardiac muscle, again suggesting that the inhibitor was blocking p38 activity ( Figure 4A ). Wt and Dusp1/4 −/− mice were administered SB731445 chow beginning at 8 weeks of age for 2 months of treatment (6 mice per group). Mice were subjected to echocardiography every 2 weeks and euthanized at 4 months of age for measurement of heart weights (echo started 4 weeks before treatment began). p38 inhibition with SB731445 prevented the increase in heart weight, prevented ventricular dilation, and prevented loss of fractional shortening in Dusp1/4 −/− mice compared with vehicle-treated DKO mice over the next 2 months of treatment ( Figure 4B-E) . Moreover, the known lethality in DKO mice with acute TAC stimulation was partially protected by SB731445 ( Figure 4F ). Inhibitor treatment of Wt mice had no effect in any of the parameters evaluated here. These results suggest that unrestrained p38 activity is the primary reason for dilated cardiomyopathy and hypertrophy in Dusp1/4 −/− mice, again suggesting that other MAPKs, such as JNK and ERK1/2, are not appreciably involved.
p38 Negatively Regulates Cardiac Contractility in
Dusp1/4 −/− Mice
To probe more deeply into the mechanism of cardiomyopathy associated with unrestrained p38 activity in Dusp1/4 −/− mice, we assessed cardiac contractility at the whole organ and cellular levels. p38 activity was previously suggested to reduce the sensitivity of myofilaments to Ca 2+ , thus acting as a negative inotrope. 21 Consistent with these results, 2-month-old Dusp1/4 −/− mice showed reduced systolic contractile performance with a Millar pressure-transducing catheter ( Figure  5A ). Dusp1/4 −/− mice also showed decreased relaxation, collectively suggesting that increased p38 activity affected systolic and diastolic performances ( Figure 5B ). However, a parallel group of mice also was acutely treated with SB731445 chow for 2 weeks and assessed for contractile changes, which showed no rescue in systolic performance but showed a significant rescue in relaxation and diastolic performance ( Figure  5A-B) . These results suggest that p38 activity is acutely involved in cardiomyocyte contractility.
Isolation of adult myocytes from 2-month-old Wt control and Dusp1/4 −/− hearts also revealed a reduction in cellular contractile performance from DKO mice ( Figures 5C and 5G) . Associated with this reduction in myocyte contractility was a reduction in peak Ca 2+ release, a reduction in sarcoplasmic reticulum Ca 2+ content, and prolonged relaxation times ( Figure  5C -F). Acute administration of the p38 inhibitor SB239063 for 10 minutes reversed all these effects in the DKO adult cardiomyocytes, suggesting that acute phosphorylation events by p38 directly dampened contractility, although it is not clear if such effects are through phosphorylation of myofilament proteins, Ca 2+ handling proteins, or both. These results provide additional mechanistic insight into how enhanced p38 activity negatively impacts the heart and how DUSP1/4 are protective by maintaining contractile performance.
To gain greater insight into the mechanism of how p38 affects contractility and secondary propensity to cardiomyopathy, we crossed Dusp1/4 −/− mice with mice lacking Pln (phospholamban). The rationale here is that if deletion of Pln complemented (rescued) the contractile deficits in Dusp1/4 −/− mice, then it would suggest a mechanism primarily involving sarcoplasmic reticulum Ca 2+ handling but not myofilament Ca 2+ sensitivity. The mice were analyzed at 4 months of age and show that DKO/Pln null mice had a restoration in fractional shortening and prevention of ventricular dilation compared with Dusp1/4 DKO-only mice ( Figure 6A-C) . These results suggest that loss of Pln, which enhances sarcoplasmic reticulum Ca 2+ cycling, can partially restore function and prevent aspects of cardiomyopathy in DKO hearts, further suggesting that p38 regulates Ca 2+ cycling as a mechanism for mediating decreased contractility when activated.
Discussion
Of the 10 Dusp genes, 5 have been reported to prefer p38 and JNK for dephosphorylation over ERK1/2, including Dusp1, Dusp4, Dusp8, Dusp10, and Dusp16. 7 However, some literature is in disagreement and differences in substrate specificity have been reported. For example, DUSP4 (MKP-2) was suggested to primarily regulate ERK1/2, then JNK, but not p38 in cultured cells, although in vivo regulation of ERK1/2 was not observed. 22 Before the generation of genedeleted mice (and null MEFs), it was often difficult to ascertain the true specificity of a given DUSP protein for a MAPK subfamily member in vitro because of promiscuity associated with reconstitution assays that fail to mimic true physiologic concentrations and subcompartmentation, as it would occur in a cell. Analysis in cultured cells also was confusing because it often relied on overexpression or partial gene knockdown approaches, which again did not mimic known physiologic concentrations of the DUSPs. Hence, the potentially only reliable means of assessing DUSP "physiologic" specificity is using gene-deleted cells or tissues to then probe for upregulation in selected MAPK members. Moreover, regulation even varies by tissue or cell type, depending on the levels of each DUSP expressed, the levels of other interacting proteins that support a complex between DUSP-MAPKs, and the levels of the individual MAPKs themselves and even their nuclear versus cytoplasmic localization. Thus, every tissue or cell type could have a unique profile of MAPK subfamily member regulation by an individual DUSP, depending on what other DUSPs are expressed and the relative content of each MAPK subfamily member. We have generated or obtained gene-deleted mice for 7 of the 10 Dusp genes, and only DUSP1, DUSP4, and DUSP10 appear to dominantly regulate p38 MAPK dephosphorylation in the heart and MEFs (results shown here and data not shown). DUSP8 appears to be mostly specific for JNK in the heart (data not shown), and DUSP6 is entirely specific for ERK1/2 in the heart and MEFs. 13 Single disruption of Dusp1, Dusp4, or Dusp10 did not appreciably impact baseline or inducible p38 MAPK phosphorylation status attributable to compensation, although Dusp1/4 double-null MEFs and hearts from these DKO mice showed a dramatic and specific effect on only p38 MAPK phosphorylation, suggesting that these 2 DUSPs are the primary regulators of p38 in vivo, or suggesting that no remaining DUSPs are present in the heart with sufficient activity or specificity for p38. However, our loss-of-function results do not prove that DUSP1/4 cannot additionally affect JNK, because other DUSPs are still present that could potentially compensate for the loss of DUSP1/4, especially if they had preference for JNK over p38 (ie, DUSP8). The critical aspect underlying our results is that loss of DUSP1/4 appears to account for the majority of DUSP activity toward p38 MAPK in fibroblasts and the heart, because the remaining 8 Dusp genes are not sufficient to fully inactivate p38 MAPK.
Another issue to consider is how MAPK activity is assessed in interpreting the effects of DUSP deletion. Although the field relies heavily on direct assessment of ERK1/2, JNK, and p38 phosphorylation using phosphospecific antibodies, it is still arguably better to examine direct downstream targets of each MAPK. However, we have determined that this is not a trivial order, because MK2 appears to be the only truly specific target of any of the MAPK family members (at least for p38 activity in heart). We surveyed a number of reported ERK-specific phosphorylation sites in different target proteins, such as Elk-1, but none was affected in hearts of our Dusp1/4 DKO mice, nor was it affected in Erk1/2 double heart-specific deleted mice that we generated previously. 23 c-Jun also is thought to be a specific target of JNK1/2, but p38 also can phosphorylate this target. However, c-Jun phosphorylation levels also were not changed in the hearts of our Dusp1/4 DKO mice, which is still consistent with DUSP1/4 only dominantly regulating p38 MAPK.
DUSP1 and DUSP4 both are thought to be primarily localized to the nucleus, thus it is difficult to envision how a specific alteration in nuclear p38 phosphorylation would lead to acute changes in myocyte contractility. However, DUSP1/4 both show some degree of localization and function within the cytosol. For example, some DUSP1 was observed within the cytosol of arterial smooth muscle cells, and some DUSP4 was similarly observed in the cytosol of cultured endothelial cells. 24, 25 Another issue related to subcellular compartments was suggested by the observation that p38 within the nucleus can activate MK2 and mediate its nuclear extrusion into the cytosol. 26 Wang et al 27 showed that the failure and hypertrophic cardiomyopathic phenotype observed in activated MKK3 transgenic mice was reduced in mice lacking the gene encoding MK2. However, activated p38 promoted greater MK2 nuclear occupancy, not its extrusion, suggesting that in the adult heart of Dusp1/4 −/− mice MK2 might have deleterious functions in the nucleus that are p38-dependent.
Dusp1/4 −/− mice have development of cardiomyopathy with aging, such that by 8 months the ventricular chambers have dilated and function is significantly diminished, the start of which can be observed as early as 2.5 months of age. In addition, 2-month-old Dusp1/4 −/− mice show exaggerated hypertrophic enlargement after 2 weeks of pressure overload stimulation compared with a normal hypertrophic response in the single-null mice and Wt mice. These results clearly indicate that Dusp1/4 are cardioprotective genes, and because the only identifiable molecular effect consistent with the known function of the Dusp gene family is an increase in p38 MAPK activity, we assume that unrestrained p38 activity underlies the cardiomyopathic phenotype in these DKO mice. Proof for this assumption came from the use of SB731445 over 2 months in Dusp1/4 −/− mice, which prevented cardiac disease. These results suggest that prolonged p38 MAPK activity in the heart induces pathology, consistent with the phenotype of transgenic mice expressing an activated mutant of MKK6 specifically in cardiomyocytes of the heart, which showed restrictive hypertrophy and lethality, whereas activated MKK3 transgenic mice showed dilated cardiomyopathy with lethality. 4 However, unlike MKK3/6 transgenic mice that presumably show nearmaximal p38 activity at all times, combined loss Dusp1/4 does not induce p38 activity; it merely removes a necessary "brake," thus allowing prolongation in activation as long as a "physiologic" stimulus is present. Hence, our results suggest that increased p38 activity in the heart is profoundly pathologic and could be a novel target for inhibition in treating patients with heart failure or select disease states that lead to hypertrophy and fibrosis, such as muscular dystrophy. A hamster model of muscular dystrophy and associated heart disease showed less fibrosis and better cardiac function with systemic p38 MAPK inhibitor treatment. 28 Similar cardioprotection also was observed in diabetic mice treated with a p38 MAPK inhibitor 29 or in mice after myocardial infarction injury. 30 In contrast, we also performed a study in 8-month-old Dusp1/4 −/− mice treated with SB731445 for 8 weeks and failed to observe any reversal in pathology, suggesting that once cardiomyopathy is established, inhibition of p38 may not be effective (data not shown).
One potential mechanism whereby prolonged p38 MAPK activity could lead to cardiac pathology is through a reduction in contractile performance. Previously, p38 MAPK activation with adenoviral-based overexpression of an activated MKK3 mutant showed reduced contractile performance of adult rat cardiac myocytes, which was reversed with a p38 inhibitory compound. 4 Whereas Liao et al. 4 never directly identified a mechanism of action whereby p38 negatively impacted contractility, they failed to observe a change in Ca 2+ handling, suggesting that the effect was at the level of the myofilament. Detergent-skinned papillary muscle strips from transgenic mice expressing an activated MKK6 mutant protein in the heart showed a reduction in maximum tension and ATPase activity, suggesting that p38 was dampening contractility at the level of myofilament proteins. 31 We similarly observed a reduction in myocyte contractility with enhanced p38 activity attributable to Dusp1/4 deletion, which was reversed with SB239063 in minutes, suggesting that regulation of contractility was attributable to immediate phosphorylation of ≥1 proteins. Crossing into the Pln-null background, which partially prevented disease and enhanced cardiac contractility in Dusp1/4 DKO mice, suggests that part of the regulation by p38 is through affecting ≥1 Ca 2+ handling proteins, presumably at the level of sarcoplasmic reticulum.
Hence, Dusp1/4 −/− mice most likely have a chronic reduction in cardiac contractility because of attenuated Ca 2+ cycling, which then likely requires neuroendocrine enhancement to maintain cardiac output, leading to a secondary hastening of disease. Sustained neuroendocrine drive is known to cause hypertrophy or augment heart failure. 32 More importantly, because p38 MAPK is activated in a semisustained manner in failing human hearts, 33 and because p38 inhibitors appear to slightly but significantly augment cardiac contractile performance in diseased myocytes, drugs that block p38 could be of further benefit in heart failure patients. 32 Finally, in addition to alterations in contractility and associated Ca 2+ handling, it is likely that unrestrained activation of p38 is pathologic and leads to dilated or hypertrophic cardiomyopathy for additional reasons, such as enhanced fibrosis and remodeling. 4, 28, 34, 35 
